Significant events during the fourth quarter 2023 (OCT-DEC)
• Mentice has received several major orders from world-leading medical technology companies.
• Mentice has appointed Ulrika Drotz Voksepp as the new CFO.
• Mentice has acquired all essential assets from Biomodex, the company´s foremost competitor within flow simulation.
• Mentice received FDA 510 (k) clearance for Ankyras™ software.

Fourth quarter (October–December 2023)
• Order intake amounted to 103.9 (90.3) MSEK, an increase of 15.0%, of which 9.2% was related to the currency effect.
• Order book by the end of the period was 156.3 (126.0) MSEK, whereof 110.0 MSEK is expected as revenue in 2024.
• Net sales amounted to 70.4 (68.7) MSEK, an increase of 2.5%, whereof 0.7% organic.
• Earnings before interest, tax, depreciation, and amortization (EBITDA) amounted to 2.3 (11.5) MSEK.
• Net income for the period amounted to -2.8 (2.1) MSEK.
• Earnings per share (EPS) were -0.11 (0.08) SEK.
• Cash flow from operating activities amounted to -6.1 (26.0) MSEK.

Full-year (January–December 2023)
• Order intake amounted to 304.2 (252.2) MSEK, an increase of 20.6%, of which 10.6% was related to the currency effect.
• The Americas region has generated 55.8% growth for order intake in 2023 compared to 2022.
• Net sales amounted to 273.6 (218.0) MSEK, an increase of 25.5%, whereof 23.9% organic.
• Earnings before interest, tax, depreciation, and amortization (EBITDA) amounted to 24.2 (-3.9) MSEK.
• Net income for the period amounted to -2.8 (-30.7) MSEK.
• Earnings per share (EPS) were -0.11 (-1.22) SEK before and after dilution.
• Cash flow from operating activities amounted to 38.7 (14.9) MSEK.

CEO Göran Malmberg comments:
We have completed a very strong year with a fourth-quarter where we exceeded last year's order intake and sales levels despite a stronger Q1-Q3 compared to the normal distribution over a year.

In terms of order intake, for the full year, we have now passed SEK 300 million, just two years after we passed SEK 200 million. We exceeded SEK 100 million in 2017.

All three of our regions have delivered in a stable manner, with our Asian operations building strong business across the region despite a problematic market situation in China. EMEA delivered another solid year and has gone from clarity to clarity with a good balance between industry and hospital sales. Our U.S. operations is the engine of our business with a year of very strong growth driven by our industrial relationships while the hospital has delivered on a too low level for 2023. The Americas region delivers more than half of our total business and has increased its order intake by 55.8% in 2023.

Webcast presentation of the year-end report
The Year-end Report Q4 for the period October – December 2023 will be presented by CEO Göran Malmberg and CFO Ulrika Drotz on February 15, 2023, at 10:00 CET. The live broadcast is followed by a Q&A moderated by Redeye’s analyst Christian Binder. For more information on how to register, please visit https://investor.mentice.com/.

The presentation will be held in English. Participants are advised to register at least a few minutes in advance.